OpenAI acquires Orchestra Bio to expand AI-assisted drug discovery work

What happened

Mark Chen welcomed Orchestra Bio and @ashokaraj_ to OpenAI as it broadens its work in AI-assisted drug discovery. In the quoted announcement, OpenAI said it acquired Orchestra Bio, a platform for coordinating drug development, and plans to build on Rosalind, its AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients.

Reported by 3 sources

The story so far

OpenAI said it has acquired Orchestra Bio, bringing the startup’s software for coordinating drug development into its life sciences work. OpenAI’s website announcement described the acquisition as in progress, while its later post on X said it was complete. TechCrunch also reported the deal as completed and described Orchestra’s AI agents as handling tasks such as tracking finances and resolving clinical trial scheduling issues. OpenAI said Orchestra’s team and technology will contribute to Rosalind, its life sciences research model, and Rosalind Workbench, a tool intended to help researchers plan experiments and analyze results, according to TechCrunch. OpenAI said it aims to streamline biopharma teams’ drug-development operations and help new treatments reach patients; those are stated goals for the acquisition.

Keep reading

Trending now

1. 1DeepSeek Open-Sources DeepInfer and API Components, With Model and Hardware Limits
2. 2Mistral Releases Voxtral 3 Speech Models, Voice Agents API and LiveKit-Based SDK
3. 4OpenAI Rolls Out Locked Chats in ChatGPT With PIN and Biometric Access
4. 5Perplexity Adds Fully Local Mac Operation to Computer